
    
      This is a Phase 2 open-label, multicenter study to evaluate the clinical activity, safety,
      pharmacokinetics (PK), and related biomarkers of ZN-c3 in adult women with recurrent or
      persistent uterine serous carcinoma (USC).
    
  